Display options
Cite
Sánchez-Carro Y, de la Torre-Luque A, Portella MJ, et al. Relationship between immunometabolic status and cognitive performance among major depression disorder patients. Psychoneuroendocrinology. 2021;137:105631doi: 10.1016/j.psyneuen.2021.105631.
Sánchez-Carro, Y., de la Torre-Luque, A., Portella, M. J., Leal-Leturia, I., Salvat-Pujol, N., Massaneda, C., de Arriba-Arnau, A., Urretavizcaya, M., Peretó, M., Toll, A., Martínez-Ruiz, A., Ferreiros-Martinez, R., Álvarez, P., Soria, V., & López-García, P. (2021). Relationship between immunometabolic status and cognitive performance among major depression disorder patients. Psychoneuroendocrinology, 137105631. https://doi.org/10.1016/j.psyneuen.2021.105631
Sánchez-Carro, Yolanda, et al. "Relationship between immunometabolic status and cognitive performance among major depression disorder patients." Psychoneuroendocrinology vol. 137 (2021): 105631. doi: https://doi.org/10.1016/j.psyneuen.2021.105631
Sánchez-Carro Y, de la Torre-Luque A, Portella MJ, Leal-Leturia I, Salvat-Pujol N, Massaneda C, de Arriba-Arnau A, Urretavizcaya M, Peretó M, Toll A, Martínez-Ruiz A, Ferreiros-Martinez R, Álvarez P, Soria V, López-García P. Relationship between immunometabolic status and cognitive performance among major depression disorder patients. Psychoneuroendocrinology. 2021 Dec 16;137:105631. doi: 10.1016/j.psyneuen.2021.105631. Epub 2021 Dec 16. PMID: 34929555.
Copy Download .nbib Format: NLM
Share it on

Psychoneuroendocrinology. 2021 Dec 16;137:105631. doi: 10.1016/j.psyneuen.2021.105631. Epub 2021 Dec 16.

Relationship between immunometabolic status and cognitive performance among major depression disorder patients.

Psychoneuroendocrinology

Yolanda Sánchez-Carro, Alejandro de la Torre-Luque, Maria J Portella, Itziar Leal-Leturia, Neus Salvat-Pujol, Clara Massaneda, Aida de Arriba-Arnau, Mikel Urretavizcaya, Mar Peretó, Alba Toll, Antonio Martínez-Ruiz, Raquel Ferreiros-Martinez, Pilar Álvarez, Virginia Soria, Pilar López-García

Affiliations

  1. Department of Psychiatry, Universidad Autonoma de Madrid (UAM), Spain; Department of Psychiatry, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain; Center for Biomedical Research in Mental Health (CIBERSAM), Carlos III Health Institute, Madrid, Spain.
  2. Center for Biomedical Research in Mental Health (CIBERSAM), Carlos III Health Institute, Madrid, Spain; Department of Legal Medicine, Psychiatry and Pathology, Universidad Complutense de Madrid, Spain.
  3. Center for Biomedical Research in Mental Health (CIBERSAM), Carlos III Health Institute, Madrid, Spain; Biomedical Research Institute Sant Pau (IIB-Sant Pau), Universitat Autonoma de Barcelona (UAB), Spain.
  4. Bellvitge University Hospital, Department of Psychiatry, Bellvitge Biomedical Research Institute (IDIBELL), Neurosciences Group - Psychiatry and Mental Health, Barcelona, Spain; Corporació Sanitària Parc Taulí, Department of Mental Health, Sabadell, Spain.
  5. Bellvitge University Hospital, Department of Psychiatry, Bellvitge Biomedical Research Institute (IDIBELL), Neurosciences Group - Psychiatry and Mental Health, Barcelona, Spain.
  6. Center for Biomedical Research in Mental Health (CIBERSAM), Carlos III Health Institute, Madrid, Spain; Bellvitge University Hospital, Department of Psychiatry, Bellvitge Biomedical Research Institute (IDIBELL), Neurosciences Group - Psychiatry and Mental Health, Barcelona, Spain; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), Spain.
  7. Inia Neural SL, Castellón, Spain.
  8. Institute of Neuropsychiatry and Addictions, Hospital del Mar, IMIM, Barcelona, Spain.
  9. Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
  10. Service of Clinical Analysis, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
  11. Department of Psychiatry, Universidad Autonoma de Madrid (UAM), Spain; Department of Psychiatry, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain; Center for Biomedical Research in Mental Health (CIBERSAM), Carlos III Health Institute, Madrid, Spain. Electronic address: [email protected].

PMID: 34929555 DOI: 10.1016/j.psyneuen.2021.105631

Abstract

BACKGROUND: Alterations in cognitive performance have been described in patients with major depressive disorder (MDD). However, the specific risk factors of these changes are not yet known. This study aimed to explore whether inmunometabolic parameters are related to cognitive performance in MDD in comparison to healthy controls (HC) METHODS: Sample consisted of 84 MDD patients and 78 HC. Both groups were compared on the results of cognitive performance measured with the Cambridge Neuropsychological Test Automated Battery (CANTAB), the presence of metabolic syndrome (MetS) and an inflammatory/oxidative index calculated by a principal component analysis of peripheral biomarkers (tumor necrosis factor, C-reactive protein and 4-hydroxynonenal). A multiple linear regression was carried out, to study the relationship between inmunometabolic variables and the global cognitive performance, being the latter the dependent variable.

RESULTS: Significant differences were obtained in the inflammatory/oxidative index between both groups (F

LIMITATIONS: Sample size was relatively small. The cross-sectional design of the study limits the possibilities of analysis.

CONCLUSIONS: Our results provide evidence on the conjoint influence of metabolic and inflammatory dysregulation on cognitive dysfunction in MDD patients. In this way, our study opens a line of research in immunometabolic agents to deal with cognitive decline associated with MDD.

Copyright © 2021. Published by Elsevier Ltd.

Keywords: Cognitive performance; Inflammation, Oxidative stress; Major depressive disorder; Metabolic Syndrome

Publication Types